The 39 references in paper A. Kolbin S., R. Gapeshin A., S. Malyshev M., А. Колбин С., Р. Гапешин А., С. Малышев М. (2018) “Трансляционные исследования. Перспективы в России // Translational research. Prospects in Russia” / spz:neicon:vedomostincesmp:y:2015:i:1:p:40-44

1
Garrido MV, Kristensen FB, Nielsen CP, et al. Health technology assessment and health policy in Europe. WHO; 2010 (in Russian).
(check this in PDF content)
2
Habriev RU, Yagudina RI, Pravdyuk NG. Health technology assessment. Moscow: Meditsinskoe informatsionnoe agentstvo; 2013 (in Russian).
(check this in PDF content)
3
Belousov YuB, ed. Health Technology Assessment. Moscow: ОКИ; 2013 (in Russian).
(check this in PDF content)
4
Kleijnen S, George E, Goulden S, et al. Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions. Value In Health 2012; (15): 954–60.
(check this in PDF content)
5
High Level Pharmaceutical Forum. Core principles on relative effectiveness. 2008.
(check this in PDF content)
6
Available from: http:// www.inahta.net.
(check this in PDF content)
7
Wagner P, Srivastava S. New paradigms in translational science research in cancer biomarkers. Translational Research 2012; (4): 343–53.
(check this in PDF content)
8
Gartlehner G, Hansen R, Nissman D, et al. A simple and valid tool distinguished efficacy from effectiveness studies. Journal of Clinical Epidemiology 2006; (10): 1040–48.
(check this in PDF content)
9
Singal A, Higgins P, Waljee A. A Primer on Effectiveness and Efficacy Trials. Clinical and Translational Gastroenterology 2014; (5): 1–4.
(check this in PDF content)
10
Marchand E, Stice E, Rohde P, et al. Moving from efficacy to effectiveness trials in prevention research. Behaviour Research and Therapy 2011; (1): 32–41. R E F E R E N C E S Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова. Российская Федерация, 197022, Санкт-Петербург, ул. Льва Толстого, 6–8. Колбин Алексей Сергеевич. Заведующий кафедрой клинической фармакологии и доказательной медицины, профессор, д-р мед. наук. Санкт-Петербургский государственный университет. Российская Федерация, 199034, Санкт-Петербург, Университетская наб., 7–9. Гапешин Роман Андреевич. Студент. Малышев Станислав Михайлович. Студент. First Pavlov State Medical University of Saint Petersburg, 6–8 Lev Tolstoy street, Saint Petersburg, 197022,
(check this in PDF content)
11
Behnke LM, Solis A, Shulman SA, et al. Targeted Approach to Reducing Overutilization: Use of Percutaneous Coronary Intervention in Stable Coronary Artery Disease. Popul Health Manag. 2013; 16(3): 164–8.
(check this in PDF content)
12
Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003; (41): 56–61.
(check this in PDF content)
13
Hingwala J, Diamond J, Tangri N, et al. Underutilization of peritoneal dialysis: the role of the nephrologist's referral pattern. Nephrol Dial Transplant. 2013; 28(3): 732–40.
(check this in PDF content)
14
Lenfant C. Clinical Research to Clinical Practice – Lost in Translation? N Engl J Med. 2003; (349): 868–74.
(check this in PDF content)
15
Kessler R, Glasgow RE. A proposal to speed translation of healthcare research into practice: dramatic change is needed. Am J Prev Med. 2011; 40(6): 637– 644.
(check this in PDF content)
16
Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008; 337: a2390.
(check this in PDF content)
17
Sox HC. Defining comparative effectiveness research: the importance of getting it right. Med Care 2010; 48 [6 Suppl]: S7–8.
(check this in PDF content)
18
Hoagwood K, Hibbs E, Brent D, Jensen P. Introduction to the special section: efficacy and effectiveness in studies of child and adolescent psychotherapy. Journal of Consulting and Clinical Psychology 1995; (63): 683–87.
(check this in PDF content)
19
Gaglio B, Phillips S, Heurtin-Roberts S, et al. How pragmatic is it? Lessons learned using PRECIS and RE-AIM for determining pragmatic characteristics of research. Implementation Science 2014; (9): 96.
(check this in PDF content)
20
Keramaris N, Kanakaris N, Tzioupis C, et al. Translational research: From benchside to bedside. Injury 2008; (6): 643–50.
(check this in PDF content)
21
Westfall JM, Mold J, Fagnan L. Practice-based research – “Blue Highways” on the NIH roadmap. Journal of the American Medical Association 2007; 297(4): 403–6.
(check this in PDF content)
22
Balas EA, Boren SA. Yearbook of Medical Informatics. Schattauer Verlagsgesellschaft mbH. Managing Clincial Knowledge for Healthcare Improvement. Stuttgart; 2000.
(check this in PDF content)
23
Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, et al. Life cycle of translational research for medical interventions. Science 2008; 321(5894): 1298–9.
(check this in PDF content)
24
Trochim W, Kane C, Graham MJ, et al. Evaluating translational research: a process marker model. Clin Transl Sci. 2011; 4(3): 153–62.
(check this in PDF content)
25
Westfall JM, Mold J, Fagnan L. Practice-based research – ‘‘blue highways’’ on the NIH roadmap. JAMA 2007; (297): 403–6.
(check this in PDF content)
26
Dougherty D, Conway PH. The ‘‘3T’s’’ road map to transform US health care: the ‘‘how’’ of high-quality care. JAMA 2008; (299): 2319–21.
(check this in PDF content)
27
Drolet B, Lorenzi N. Translational research: understanding the continuum from bench to bedside. Translational Research 2011; (1): 1–5.
(check this in PDF content)
28
Khoury MJ, Gwinn M, Yoon PW, et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genetics in Medicine 2007; 9(10): 665–74.
(check this in PDF content)
29
Sung NS, Crowley WF Jr, Genel M, et al. Central challenges facing the national clinical research enterprise. JAMA 2003; (289): 1278–87.
(check this in PDF content)
30
Cao Y. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug? The International Journal of Developmental Biology 2011; (55): 557–62.
(check this in PDF content)
31
Wehling M. Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Discov 2009; (8): 541–46.
(check this in PDF content)
32
Wang P, Heinssen R, Oliveri M, et al. Bridging Bench and Practice: Translational Research for Schizophrenia and Other Psychotic Disorders. Neuropsychopharmacology 2009; (34): 204–12.
(check this in PDF content)
33
Schumacher A, Rujan T, Hoefkens J. A collaborative approach to develop a multi-omics data analytics platform for translational research. Appl Transl Genomic. Available from: http://dx.doi.org/10.1016/j.atg.2014.09.010.
(check this in PDF content)
34
Yao Q., Lyu P., Ma F., el al. Global infometric perspective studies on translational medical research. BMC Medical informatics and Decision Making 2013; (13): 77.
(check this in PDF content)
35
Grunseth M, Chen C, Cook S, et al. Surveying the best in translation. Nature Biotechnology 2014; 32(5): 415–18.
(check this in PDF content)
36
Отчет о проведении всероссийской научной школы «Трансляционная медицина: международный опыт и тенденции развития в России». Москва. 3 ноября 2011.
(check this in PDF content)
37
Available from: http://www.almazovcentre.ru/?page_id=10962.
(check this in PDF content)
38
Kent DM, Alsheikh-Ali A, Hayward RA. Competing risk and heterogeneity of treatment effect in clinical trials. Trials 2008, (9): 30.
(check this in PDF content)
39
Available from: http://www.re-aim.hnfe.vt.edu/forms/reaim_framework_constructs_checklist.pdf 11. Behnke LM, Solis A, Shulman SA, et al. Targeted Approach to Reducing Overutilization: Use of Percutaneous Coronary Intervention in Stable Coronary Artery Disease. Popul Health Manag. 2013; 16(3): 164–8.
(check this in PDF content)